| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 11/15/2001 | WO2001085218A2 Acylated cyclodextrin guest inclusion complexes |
| 11/15/2001 | WO2001085217A1 Gel-like pharmaceutical composition for subcutaneous administration comprising bisphosphonic acids or their salts |
| 11/15/2001 | WO2001085216A1 Method for the preparation of polymeric micelle via phase separation of block copolymer |
| 11/15/2001 | WO2001085210A2 Compositions and methods for demonstrating secretory immune system regulation of steroid hormone responsive cancer cell growth |
| 11/15/2001 | WO2001085206A2 Immunosuppressive compositions comprising an immunophilin-binding compound and a gingkolide compound |
| 11/15/2001 | WO2001085201A2 Use of il-18 inhibitors for the treatment and/or prevention of atherosclerosis |
| 11/15/2001 | WO2001085194A1 Method and composition for the treatment of angiogenesis |
| 11/15/2001 | WO2001085182A2 Combined cartilage and plant extract compositions |
| 11/15/2001 | WO2001085179A2 Biological joint lubricant composition and method of applying |
| 11/15/2001 | WO2001085178A1 Nutritional preparation comprising ribose and folic acid and medical use thereof |
| 11/15/2001 | WO2001085177A1 The meca-79 antigen and related methods |
| 11/15/2001 | WO2001085175A2 Prevention of insulin-dependent diabetes, complications thereof, or allograft rejection by inhibition of cyclooxygenase-2 activity with ns398 or pdtc |
| 11/15/2001 | WO2001085174A1 Formulations containing a glucocorticoid drug for the treatment of bronchopulmonary diseases |
| 11/15/2001 | WO2001085172A1 Novel anti-infectives |
| 11/15/2001 | WO2001085171A1 Local anesthetic methods and kits |
| 11/15/2001 | WO2001085170A1 Peptide deformylase inhibitors |
| 11/15/2001 | WO2001085169A2 R-eliprodil for treating glaucoma |
| 11/15/2001 | WO2001085168A1 Use of compounds having combined dopamine d2, 5-ht1a and alpha adrenoreceptor agonistic action for treating cns disorders |
| 11/15/2001 | WO2001085167A1 Pharmaceutical compositions comprising proton pump inhibitors and gastrin/cholecystokinin receptor ligands |
| 11/15/2001 | WO2001085166A1 Methods for inhibiting proliferation and inducing apoptosis in cancer cells |
| 11/15/2001 | WO2001085165A2 Combination of lipoic acid and c1 donors for the treatment of disorders of the central nervous system |
| 11/15/2001 | WO2001085164A1 The treatment of herpes |
| 11/15/2001 | WO2001085163A1 Treating eczema and/or psoriasis |
| 11/15/2001 | WO2001085162A1 Treating irritable bowel syndrome or disease |
| 11/15/2001 | WO2001085161A1 Combination preparation consisting of φ-3-fatty acids and of conjugated linoleic acids for treating immunologically oriented clinical signs |
| 11/15/2001 | WO2001085160A1 Peptide deformylase inhibitors |
| 11/15/2001 | WO2001085159A1 Topical anti-acne composition |
| 11/15/2001 | WO2001085158A2 Anandamide and structurally related lipids as vanilloid receptor modulators |
| 11/15/2001 | WO2001085157A1 Compositions and methods for treatment of proliferative disorders |
| 11/15/2001 | WO2001085156A1 Dermal compositions containing coenzyme q as the active ingredient |
| 11/15/2001 | WO2001085155A1 Method and compositions for inhibiting arteriosclerosis |
| 11/15/2001 | WO2001085154A2 Method of treating immune pathologies with low dose estrogen |
| 11/15/2001 | WO2001085152A2 R-eliprodil for treating glaucoma |
| 11/15/2001 | WO2001085151A2 Chimeric animal model and treatment of psoriasis |
| 11/15/2001 | WO2001085150A2 Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists |
| 11/15/2001 | WO2001085149A2 Felbamate derived compounds |
| 11/15/2001 | WO2001085148A2 Packaging regimen of pseudoephedrine hydrochloride and fexofenadine hydrocloride |
| 11/15/2001 | WO2001085147A2 STABILIZED FORMULATIONS OF 6-HYDROXY-3-(4-[2-(PIPERIDIN-1-YL) ETHOXY]PHENOXY)-2-(4-METHOXYPHENYL) BENZO[b]THIOPHENE AND SALTS THEREOF |
| 11/15/2001 | WO2001085146A1 Pharmaceutical compounds for treating copd |
| 11/15/2001 | WO2001085145A2 A pharmaceutical composition and method of treatment of diseases of cognitive dysfunction in a mammal |
| 11/15/2001 | WO2001085144A2 Use of substituted acryloyl distamycin derivatives in the treatment of tumors associated with high levels of glutathione |
| 11/15/2001 | WO2001085143A2 Pharmaceutical compositions for transdermal administration of anti-inflammatory agents |
| 11/15/2001 | WO2001085142A1 Compositions and methods for protecting cells during cancer chemotherapy and radiotherapy |
| 11/15/2001 | WO2001085140A1 Evaporative coolant comprising hydrofluorocarbons and/or hydrochlorofluorocarbons |
| 11/15/2001 | WO2001085135A1 PHARMACEUTICAL COMPOSITION CONTAINING ITRACONAZOLE WITH GASTRIC pH-INDEPENDENTLY IMPROVED SOLUBILITY AND PREPARATION METHOD THEREOF |
| 11/15/2001 | WO2001085132A1 Drug delivery device, especially for the delivery of levonorgestrel |
| 11/15/2001 | WO2001085128A2 Skin protectant spray compositions |
| 11/15/2001 | WO2001085125A2 Skin preparation |
| 11/15/2001 | WO2001085120A1 6,10-dimethyl-5,9-undecadien-2-ol |
| 11/15/2001 | WO2001085116A2 Synergistic antiplaque/antigingivitis oral composition |
| 11/15/2001 | WO2001085106A2 Cosmetic agents containing 2-furanone derivatives |
| 11/15/2001 | WO2001085096A2 Mast cell regulation |
| 11/15/2001 | WO2001085093A2 Compounds and methods for modulating cerebral amyloid angiopathy |
| 11/15/2001 | WO2001085092A2 Antidiarrheal cannabinoid cb-1 receptor antagonist |
| 11/15/2001 | WO2001085013A2 Infrared thermography and methods of use |
| 11/15/2001 | WO2001084963A1 Edible composition containing micronised nacre powder |
| 11/15/2001 | WO2001084961A2 Preparation for the prevention and/or treatment of vascular disorders |
| 11/15/2001 | WO2001084938A1 Method of inducing apoptosis with melothria indica lou extract |
| 11/15/2001 | WO2001084929A1 Antitubulin assembly and cell growth inhibitor denominated 'dioxostatin' |
| 11/15/2001 | WO2001076627A8 Treatment of fungal infections with polyene or beta glucan synthase inhibitor antifungals combined with anti hsp90 antibodies |
| 11/15/2001 | WO2001060375A8 Use of 7alpha-hydroxy-estradiol, 7alpha-hydroxy-dehydroepiandrosterone and 7alpha-hydroxy-pregnenolone derivatives for treating acute cellular degeneration |
| 11/15/2001 | WO2001047518A8 Methods of facilitating vascular growth in cardiac muscle and methods for the production of recombinant emap ii |
| 11/15/2001 | WO2001047498A3 Hydrogel-driven layered drug dosage form comprising sertraline |
| 11/15/2001 | WO2001044144A3 Process for the preparation of sodium salts of statins |
| 11/15/2001 | WO2001041733A3 Compressed tablet composition comprising a nsaid |
| 11/15/2001 | WO2001040255A3 14,15-beta-methylene substituted androgens |
| 11/15/2001 | WO2001040185B1 Compounds, compositions, and methods for stimulating neuronal growth and elongation |
| 11/15/2001 | WO2001039761B1 Administration of an alpha-2 adrenergic receptor agonist to enhance cardiopulmonary resuscitation |
| 11/15/2001 | WO2001036656A3 A complex between hyaluronic acid and a biomolecule and its use |
| 11/15/2001 | WO2001034601A3 Imidazopyridine derivatives as phosphodiesterase vii inhibitors |
| 11/15/2001 | WO2001032882A3 Nucleic acids and proteins from group b streptococcus |
| 11/15/2001 | WO2001032652A3 N-substituted carbamoyloxyalkyl-azolium derivatives |
| 11/15/2001 | WO2001022958A3 A pharmaceutical composition containing lycopene for stabilising atherosclerotic plaques |
| 11/15/2001 | WO2001019334A3 Pharmaceutical solutions of levosimendan |
| 11/15/2001 | WO2001017963A3 Aminoalkoxy carbazoles and their use as 5-ht ligands |
| 11/15/2001 | WO2001017512A3 Combination preparation for initiation of oestrus |
| 11/15/2001 | WO2001016136B1 Tricyclic inhibitors of poly(adp-ribose) polymerases |
| 11/15/2001 | WO2001015737A3 Method for coupling molecules |
| 11/15/2001 | WO2001012202A3 Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
| 11/15/2001 | WO2001009616A3 Method for determining physiological effects of hemoglobin |
| 11/15/2001 | WO2001008672A3 Glucamine compounds for treating hepatitis virus infections |
| 11/15/2001 | WO2001007088A3 Methods for treating therapy-resistant tumors |
| 11/15/2001 | WO2001006756A3 Use of diphenyliodonium for the activation and protection of cytotoxic lymphocytes |
| 11/15/2001 | WO2001002550A3 Cell death related drug targets in yeast and fungi |
| 11/15/2001 | WO2001001995A3 Method for treatment of asthma syndrome |
| 11/15/2001 | WO2001000187A3 Pharmaceutical composition containing sibutramine and a lipase inhibitor |
| 11/15/2001 | WO2000071507A3 INHIBITORS OF FACTOR Xa |
| 11/15/2001 | WO2000067737A3 USE OF HMGCoA REDUCTASE INHIBITORS IN THE PREVENTION OF DISEASES WHOSE PATHOGENESIS IS DEPENDENT ON NEOVASCULARIZATION |
| 11/15/2001 | WO2000064484A3 Conjugate having a cleavable linkage for use in a liposome |
| 11/15/2001 | WO2000063379A3 The p2x3 receptor, methods of altering p2x3 receptor activity and uses thereof |
| 11/15/2001 | WO2000057865A9 Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation |
| 11/15/2001 | WO2000055323A9 Differential expression of organellar gene products |
| 11/15/2001 | WO2000051582A3 Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron |
| 11/15/2001 | WO2000051548A3 COMPOSITIONS AND METHODS FOR THEIR PREPARATION FROM $i(LEPIDIUM) |
| 11/15/2001 | WO2000050872A9 A system for cell-based screening |
| 11/15/2001 | WO2000044216A8 Gambogic acid, analogs and derivatives as activators of caspases and inducers of apoptosis |
| 11/15/2001 | WO2000041541A3 Method of isolating mucilaginous polysaccharides and uses thereof |
| 11/15/2001 | WO2000026370A9 Adenine nucleotide translocator (ant) fusion proteins and uses thereof |
| 11/15/2001 | US20010041964 Pharmacokinetic-based drug design tool and method |
| 11/15/2001 | US20010041923 Patient temperature regulation method and apparatus |